Sonnet BioTherapeutics Partners with Alkem for SON-080 Development
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) has made a significant move by entering a licensing agreement with Alkem Laboratories Limited. This strategic collaboration is focused on the development and commercialization of SON-080, which targets diabetic peripheral neuropathy (DPN) in India. As part of the agreement, Sonnet will receive $1.0 million upfront and potential milestone payments totaling another $1.0 million, plus royalties on net sales in the Indian market.
The Growing Need for Diabetic Neuropathy Treatment
The condition commonly known as DPN affects nearly half of diabetic patients, causing extreme pain and disability. Current available therapies majorly focus on pain relief, leaving a gap in treatment options for non-pain symptoms that stem from nerve damage. In India, the diabetic neuropathy market was estimated to be valued at approximately $120.3 million in 2023, with projections suggesting it could reach $246.7 million by 2030.
Sonnet's Innovative SON-080 Approach
SON-080 is a proprietary formulation of recombinant human Interleukin-6 (rhIL-6). The drug aims to stimulate peripheral nerve growth, thereby alleviating symptoms of DPN. Prior clinical trials have shown promising safety and efficacy results, indicating the potential to prevent and reverse neuropathy through low-dose administration.
Collaboration with Alkem Laboratories
Under this partnership, Alkem will be responsible for funding, developing, and promoting SON-080 for DPN, as well as for other neuropathies like Chemotherapy-Induced Neuropathy (CIPN) and Autonomic Neuropathy. Alkem's robust experience in the Indian pharmaceutical landscape positions them as a suitable partner for this venture. Sonnet will have the opportunity to leverage clinical data from Alkem's Phase 2 and Phase 3 trials in future collaborations in markets outside India.
Positive Clinical Results and Future Prospects
Recently, Sonnet shared data from its Phase 1b/2a clinical trial assessing SON-080 for CIPN, indicating the drug was well-tolerated with no harmful cytokine responses observed. Patient feedback highlighted rapid improvements in symptoms, showcasing the potential therapeutic benefits of SON-080. Sonnet is eager to expand this program and find additional partnership opportunities that could lead to a Phase 2 trial.
The Role of Leadership in this Partnership
Pankaj Mohan, CEO of Sonnet BioTherapeutics, expressed optimism about the collaboration, emphasizing Alkem’s expertise as vital for advancing SON-080 through clinical development. He underscored the significance of addressing the unmet medical needs of DPN patients globally.
About Alkem Laboratories Limited
Alkem Laboratories is a leading Indian pharmaceutical entity, recognized for its commitment to producing high-quality medications. With 50 years of experience, Alkem has established a diverse product portfolio that spans various therapy areas, including anti-infectives and neurology. Through its extensive facilities and R&D capabilities, Alkem is set to make a significant impact in the pharmaceutical domain.
About Sonnet BioTherapeutics Holdings, Inc.
Sonnet is an innovative biotechnology firm focused on developing targeted biologics, utilizing its proprietary FHAB technology. This advancement allows for refined delivery of therapeutic substances to combat cancer and other serious medical conditions. Sonnet is currently optimizing its lead program, SON-1010, targeting solid tumors and collaborating with Roche to enhance treatment outcomes.
Frequently Asked Questions
What is SON-080 developed for?
SON-080 is being developed to treat diabetic peripheral neuropathy (DPN) and other neurological disorders like chemotherapy-induced neuropathy.
What does the partnership with Alkem involve?
Alkem will fund, develop, and promote SON-080 in India, while Sonnet will receive upfront and milestone payments along with royalties from sales.
How large is the diabetic neuropathy market in India?
The market size for diabetic neuropathy in India is expected to grow from $120.3 million in 2023 to $246.7 million by 2030.
What is the significance of the clinical trial data for SON-080?
The clinical trial data for SON-080 indicates it is well-tolerated and has the potential to significantly alleviate symptoms of neuropathy, leading to improved patient outcomes.
What future plans does Sonnet have for SON-080?
Sonnet aims to expand SON-080’s program into Phase 2 trials and explore additional partnerships for further development opportunities.
